NO20034916D0 - Anvendelse av glukokortikoid reseptor-spesifikke antagonister ved behandling av delirium - Google Patents
Anvendelse av glukokortikoid reseptor-spesifikke antagonister ved behandling av deliriumInfo
- Publication number
- NO20034916D0 NO20034916D0 NO20034916A NO20034916A NO20034916D0 NO 20034916 D0 NO20034916 D0 NO 20034916D0 NO 20034916 A NO20034916 A NO 20034916A NO 20034916 A NO20034916 A NO 20034916A NO 20034916 D0 NO20034916 D0 NO 20034916D0
- Authority
- NO
- Norway
- Prior art keywords
- glucocorticoid receptor
- delirium
- treatment
- receptor antagonist
- specific antagonists
- Prior art date
Links
- 206010012218 Delirium Diseases 0.000 title abstract 3
- 102000003676 Glucocorticoid Receptors Human genes 0.000 title 1
- 108090000079 Glucocorticoid Receptors Proteins 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 229940126013 glucocorticoid receptor antagonist Drugs 0.000 abstract 3
- 239000003850 glucocorticoid receptor antagonist Substances 0.000 abstract 3
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229960000890 hydrocortisone Drugs 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- VKHAHZOOUSRJNA-GCNJZUOMSA-N mifepristone Chemical compound C1([C@@H]2C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]3CC[C@@]([C@]3(C2)C)(O)C#CC)=CC=C(N(C)C)C=C1 VKHAHZOOUSRJNA-GCNJZUOMSA-N 0.000 abstract 1
- 229960003248 mifepristone Drugs 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28861901P | 2001-05-04 | 2001-05-04 | |
| US13780002A | 2002-05-01 | 2002-05-01 | |
| PCT/US2002/014318 WO2002096433A1 (en) | 2001-05-04 | 2002-05-06 | Methods for treating delirium using glucocorticoid receptor-specific antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20034916D0 true NO20034916D0 (no) | 2003-11-04 |
| NO20034916L NO20034916L (no) | 2004-01-05 |
| NO334736B1 NO334736B1 (no) | 2014-05-19 |
Family
ID=26835589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20034916A NO334736B1 (no) | 2001-05-04 | 2003-11-04 | Glukokortikoidreseptorantagonist for anvendelse ved behandling av delirium |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP1390037B1 (no) |
| JP (2) | JP2005512949A (no) |
| CN (1) | CN1527713A (no) |
| AT (1) | ATE492281T1 (no) |
| AU (1) | AU2002303652B2 (no) |
| CA (1) | CA2446506C (no) |
| DE (1) | DE60238671D1 (no) |
| IL (2) | IL158744A0 (no) |
| NO (1) | NO334736B1 (no) |
| NZ (1) | NZ529456A (no) |
| WO (1) | WO2002096433A1 (no) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1441739B1 (en) * | 2001-10-26 | 2006-02-15 | Akzo Nobel N.V. | Use of (11beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one in the treatment of major depressive disorder |
| BR112014007910A2 (pt) * | 2011-10-07 | 2017-04-18 | Koninklijke Philips Nv | sistema para monitoramento automatizado de um paciente e detectar delírio do paciente, método para monitorar automaticamente um paciente, processador para utilização em um sistema de monitoramento automático para monitorar um paciente, método de processamento, e programa de computador |
| CN116168840B (zh) * | 2023-04-23 | 2023-12-22 | 北京大学人民医院 | 一种预测术后谵妄发生风险的方法、设备及系统 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3464012B2 (ja) * | 1993-04-05 | 2003-11-05 | 旭化成株式会社 | 精神症候治療剤 |
| IL110309A0 (en) * | 1993-07-15 | 1994-10-21 | Univ Kentucky Res Found | A method of protecting against neuron loss |
| KR100840957B1 (ko) * | 1997-10-06 | 2008-06-24 | 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 | 글루코코르티코이드 관련 장애와 관련된 정신병을 치료하는방법 |
| WO1999059596A1 (en) * | 1998-05-15 | 1999-11-25 | The Board Of Trustees Of Leland Stanford Junior University | Glucocorticoid receptor antagonists for the treatment of dementia |
| JP2004525135A (ja) * | 2001-03-23 | 2004-08-19 | コーセプト セラピューティクス， インコーポレイテッド | 糖質コルチコイドレセプター特異的アンタゴニストを使用するストレス障害を処置するための方法 |
-
2002
- 2002-05-06 DE DE60238671T patent/DE60238671D1/de not_active Expired - Lifetime
- 2002-05-06 AU AU2002303652A patent/AU2002303652B2/en not_active Ceased
- 2002-05-06 CA CA2446506A patent/CA2446506C/en not_active Expired - Fee Related
- 2002-05-06 AT AT02731689T patent/ATE492281T1/de active
- 2002-05-06 EP EP02731689A patent/EP1390037B1/en not_active Expired - Lifetime
- 2002-05-06 WO PCT/US2002/014318 patent/WO2002096433A1/en not_active Ceased
- 2002-05-06 CN CNA028126726A patent/CN1527713A/zh active Pending
- 2002-05-06 IL IL15874402A patent/IL158744A0/xx unknown
- 2002-05-06 NZ NZ529456A patent/NZ529456A/en not_active IP Right Cessation
- 2002-05-06 JP JP2002592943A patent/JP2005512949A/ja active Pending
-
2003
- 2003-11-04 NO NO20034916A patent/NO334736B1/no not_active IP Right Cessation
- 2003-11-04 IL IL158744A patent/IL158744A/en not_active IP Right Cessation
-
2008
- 2008-12-09 JP JP2008313766A patent/JP2009102346A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009102346A (ja) | 2009-05-14 |
| WO2002096433A9 (en) | 2003-02-06 |
| ATE492281T1 (de) | 2011-01-15 |
| HK1059036A1 (en) | 2004-06-18 |
| CA2446506C (en) | 2012-04-10 |
| NZ529456A (en) | 2005-10-28 |
| IL158744A0 (en) | 2004-05-12 |
| DE60238671D1 (de) | 2011-02-03 |
| AU2002303652B2 (en) | 2006-08-31 |
| WO2002096433A1 (en) | 2002-12-05 |
| NO334736B1 (no) | 2014-05-19 |
| EP1390037B1 (en) | 2010-12-22 |
| EP1390037A4 (en) | 2005-03-30 |
| CA2446506A1 (en) | 2002-12-05 |
| NO20034916L (no) | 2004-01-05 |
| JP2005512949A (ja) | 2005-05-12 |
| CN1527713A (zh) | 2004-09-08 |
| EP1390037A1 (en) | 2004-02-25 |
| IL158744A (en) | 2011-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1108562T1 (el) | Μεθοδοι για την προληψη προσληψης βαρους η οποια προκαλειται απο αντιψυχωτικες θεραπειες | |
| WO2002076390A3 (en) | Methods for treating stress disorders using glucocorticoid receptor-specific antagonists | |
| DE69833502D1 (de) | Glucocorticoid receptor antagonisten zur behandlung von demenz | |
| DE69835225D1 (de) | Methode zur behandlung von durch glycocorticoidstörungen verursachten psychosen | |
| WO2004058717A8 (en) | Isoquinolinone derivatives and their use as therapeutic agents | |
| NO20003534D0 (no) | Progesteronreseptor-modulatorforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsene | |
| ATE450508T1 (de) | Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren | |
| HK1047050A1 (zh) | 治疗轻度智力机能缺陷的方法 | |
| DE60228073D1 (de) | Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen | |
| IL164793A0 (en) | Methods for increasing the therapeutic response toelectroconvulsive therapy ("ect") | |
| DE60229411D1 (de) | Verfahren zur hemmung der verschlechterung der kognitiven leistungsfähigkeit bei erwachsenen mit down-syndrom | |
| WO2004069202A3 (en) | Antiglucocorticoids for the treatment of postpartum psychosis | |
| NO20034916L (no) | Anvendelse av glukokortikoid reseptor-spesifikke antagonister ved behandling av delirium | |
| MX2007003545A (es) | Composiciones y metodos para tratar trastornos cognitivos. | |
| DE60006948D1 (de) | Antagonismus des estrogen-rezeptors-beta und knochenkrankheiten | |
| WO2002020526A3 (en) | Cyclic and acyclic amidines and pharmaceutical compositions containing them for use as progesterone receptor binding agents | |
| AU2002219192A1 (en) | Dissociated glucocorticoid receptor antagonists for the treatment of clucocorticoid associated side-effect | |
| EP1726307A3 (en) | Methods for treating psychosis associated with glucocorticoid related dysfunction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |